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Abstract: The heterogeneity of glioblastomas, the most common primary malignant brain tumor,
remains a significant challenge for the treatment of these devastating tumors. Therefore, novel
combination treatments are warranted. Here, we showed that the combined inhibition of TRAP1
by gamitrinib and histone deacetylases (HDAC1/HDAC2) through romidepsin or panobinostat
caused synergistic growth reduction of established and patient-derived xenograft (PDX) glioblastoma
cells. This was accompanied by enhanced cell death with features of apoptosis and activation
of caspases. The combination treatment modulated the levels of pro- and anti-apoptotic Bcl-2
family members, including BIM and Noxa, Mcl-1, Bcl-2 and Bcl-xL. Silencing of Noxa, BAK and
BAX attenuated the effects of the combination treatment. At the metabolic level, the combination
treatment led to an enhanced reduction of oxygen consumption rate and elicited an unfolded stress
response. Finally, we tested whether the combination treatment of gamitrinib and panobinostat
exerted therapeutic efficacy in PDX models of glioblastoma (GBM) in mice. While single treatments
led to mild to moderate reduction in tumor growth, the combination treatment suppressed tumor
growth significantly stronger than single treatments without induction of toxicity. Taken together, we
have provided evidence that simultaneous targeting of TRAP1 and HDAC1/2 is efficacious to reduce
tumor growth in model systems of glioblastoma.
Keywords: glioblastoma; gamitrinib; HDAC inhibitors; tumor metabolism; electron transport chain;
Bcl-2 family

1. Introduction
Patients suffering from glioblastoma (GBM), the most common primary malignant brain tumor,
still require more efficient therapies to extend the so far unsatisfying overall survival between twelve
to fifteen months [1,2]. Although significant progress has been made with regards to the molecular
characterization, this knowledge, thus far, has not led to fruition in terms of better treatments. What
remains clear is that glioblastomas are amongst the most heterogeneous cancers and this pivotal
observation clearly suggests that drug combination treatments are likely the key to achieve a better
prognosis for this disease [1–3].
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Proceeding with this premise, we have conducted a high-throughput drug screen and found that
mitochondrial matrix chaperone inhibitors that are in preparation for clinical testing cause synthetic
lethality in the presence of selective or global histone deacetylase (HDAC) inhibitors in cancer cells [4].
Represented by the lead compound gamitrinib (GTPP) mitochondrial matrix chaperone inhibitors
have shown anti-cancer activity in several tumor model systems, including prostate cancer, colon
cancer, lymphoma, leukemia and glioblastoma [5–7]. With regards to the underlying mechanisms,
gamitrinib was linked to mitochondrial permeability related cell death akin to its related predecessor,
the Hsp90 inhibitor peptide shepherdin [8,9], which interferes with both cytosolic and mitochondrial
Hsp90. Another compelling mechanism is the notion that TRAP1 (the molecular target of gamitrinib)
is a major chaperone for the respiratory complexes of the electron transport chain and consequently
interference with TRAP1 disintegrates oxidative phosphorylation [10]. Global (panobinostat) and
selective (romidepsin (HDAC1 and 2)) HDAC inhibitors are FDA-approved drugs, known for their
efficacy against multiple myeloma [11]. However, to date, these molecules have fallen short of
expectation in the context of glioblastoma treatment [12], emphasizing the need for combination
treatments. Recent findings from our lab have highlighted that in GBM model systems HDAC
inhibitors block glycolysis and in turn activate oxidative phosphorylation fueled by fatty acid oxidation
to counteract cell death and inhibition of proliferation [13]. Therefore, blocking the electron transport
chain by TRAP1 antagonist may likely enhance the killing effect of FDA approved HDAC inhibitors in
GBM cells.
Here, we show that pan and selective HDAC inhibition is indeed synthetically lethal with TRAP1
inhibition in various model systems of glioblastoma, including patient-derived xenograft (PDX) cells.
Mechanistically, this occurs through several processes, including the induction of metabolic stress by
interference with tumor cell energy metabolism accompanied by modulation of pro- and anti-apoptotic
Bcl-2 family proteins and the induction of a cell death with apoptotic features.
2. Material and Methods
2.1. Cell Cultures and Growth Conditions
The indicated cell cultures were grown and maintained at 37 ◦ C supplemented with 5% CO2 . U87,
LN229 and T98G cell lines were obtained from the American Type Culture Collection (Manassas, VA,
USA). U251 cell line was obtained from Sigma (St. Louis, MO, USA). GBM12, GBM14 and GBM43
were obtained from Dr. Jann Sarkaria (Mayo Clinic, Rochester, MN, USA). Cells were cultured in
Dulbecco’s Modified Eagle Medium (DMEM) (Fisher Scientific (Waltham, MA, USA), MT10013CV),
supplemented with 10% FBS (Gemini, FBS002) and 100 µg/mL of Primocin (Invivogen (San Diego, CA,
USA), ant-pm-1). For the treatment experiment, cells were cultured in DMEM containing 1.5% FBS
and primocin. The U87 PbR were exposed with 100 nM panobinostat for a week.
2.2. Reagents
The TRAP1 inhibitor, Gamitrinib (GTPP), was a gift from Dr. Dario Altieri (Wistar Institute,
Philadelphia, PA, USA). Z-VAD-FMK (HY-16658B), panobinostat (HY-10224) and romidepsin (HY-15149)
were purchased from MedChemExpress (Monmouth Junction, NJ, USA). A 10 mM working solution in
dimethylsulfoxide (DMSO) was prepared for all reagents prior to storage at −20 ◦ C. Final concentrations
of DMSO were below 0.1% (v/v).
2.3. Cell Viability Assays
Cells were seeded in 96-well plates and allowed to attach overnight. Cells were treated with
different doses of indicated drugs for 72 h and CellTiter-Glo® assays (Promega (Madison, WI, USA),
G7571) were performed according to the manufacturer’s instruction. We employed the median-effect
equation (Chou-Talalay), to evaluate drug synergy. Following calculations, this approach yields
normalized isobolograms and the combination index (CI), respectively [14].
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2.4. Flow Cytometry
Cells were treated with drug compounds for the indicated time frames and processed for staining
in accordance with the manufacturers’ instructions. To detect apoptosis, the Annexin V Apoptosis
Detection Kit (BD Pharmingen (Franklin Lakes, NJ, USA), BD 556419) was used. To measure the
subG1/G0 fraction following treatments, the Propidium Iodide (PI)/RNase Staining Solution was
employed (Cell Signaling Technology (Danvers, MA, USA), CST 4087S). To detect mitochondrial
membrane potential, Mitochondrial Membrane Potential kit (CST 13296S) was used. The FlowJo
software (version 10.6.2; Tree Star, Ashland, OR, USA) was employed for the entire analysis of the
collected data.
2.5. Transfection of siRNAs
Transfections were performed with Lipofectamine RNAiMAX (Invitrogen (Carlsbad, CA, USA),
13778075) according to the manufacturers’ instructions. Non-targeting siRNA-pool (D-001810-10-20),
siTRAP1 (L-010104-00-0005), siBax (L-003308-01-0005) and siATF4 (L-005125-00-0005) were purchased
from Dharmacon (Lafayette, CO, USA). siPMAIP1 (siNoxa, 4392420) and siBAK (4390824) were
purchased from Ambion (ThermoFisher, Waltham, MA, USA).
2.6. Extracellular Flux Analysis
Both the oxygen consumption rate (OCR) and the extracellular acidification rate (ECAR) were
determined on the Seahorse XFe24 analyzer in accordance with the manufacturers’ instructions
(Agilent Technologies, Santa Clara, CA, USA). XFe24 cell culture microplates (Agilent) were used
for the experiments and U87 GBM cells were cultured in DMEM containing 5 mM Glucose,
1 mM Glutamine and 10% FBS. Following adherence overnight, treatments (24 h) were administered in
the same medium except that 1.5% FBS was used. Mitochondrial stress assay was performed in the
Seahorse XF base medium (Agilent, 102353-100) containing 10 mM glucose, 2 mM glutamine, 1 mM
pyruvate. The following compounds were injected in a sequential order—2 µmol/L oligomycin (OM),
2 µmol/L Carbonyl cyanide-4 (trifluoromethoxy) phenylhydrazone (FCCP) and 0.5 µmol/L rotenone/
antimycin (R/A).
2.7. Western Blot Analysis
Protein expression was determined by western blot analysis (Invitrogen, NP0321BOX) or protein
capillary electrophoresis (Protein Simple (San Jose, CA, USA) SM-W004). Primary antibody incubations
were performed overnight at 4 ◦ C. For standard western blot, the following antibodies were applied
PARP (CST 9532; 1:500); cCP9 (CST 7237; 1:500); cCP3 (CST 9665; 1:500); Tubulin (Sigma T5168;
1:1000); Mcl-1 (CST 5453; 1:500); Bcl-xL (CST 2764; 1:500); Bcl-2 (CST 4223; 1:500); BIM (CST 2933;
1:500), Noxa (Calbiochem (Burlington, MA, USA) OP180, clone 114C307; 1:500), Vinculin (Abcam
(Cambridge, MA, USA) ab129002, 1:500), OXPHOS (Abcam ab110411;1:500); β-actin (Sigma Aldrich
A1978, clone AC15; 1:2,000). TRAP1 (Novus Biological (Littleton, CO, USA), NBP2-20700, 1:500),
SDHA (Abcam ab123545; 1:500), SDHB (Abcam ab154974; 1:500). For protein capillary electrophoresis,
the following antibodies were applied ATF3 (Novus Biological NBP1-85816; 1:25); ATF4 (CST 11815;
1:25), GRP78 (BiP-CST 3177; 1:100); elF2α (CST 9722; 1:25), p- elF2α (CST 3398; 1:25), CHOP (CST
2895; 1:25), Noxa (Calbiochem OP180, clone 114C307; 1:25). The HRP linked secondary antibodies
were from Santa Cruz Biotechnology Inc. Western blots were visualized on the Azure (C300) imaging
system (chemiluminescence based). The uncropped images are quantified and presented in the
Supplementary section.
2.8. Real-Time PCR Analysis
The miRNAeasy Mini Kit (QIAGEN 217004) was employed to harvest RNA following treatments.
Following capture of the RNA, reverse-transcription was performed (cDNA synthesis kit (Quantabio
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101414-106)). The SYBR green Real time PCR (RT-PCR) reagents kit (Quantabio 101414-276) was
utilized as the reaction mix. The settings for the RT-PCR machine (Quantabio) are as follows—95 ◦ C
for 10 min, followed by 40 cycles of 95 ◦ C for 15 s, 60 ◦ C for 30 s and 72 ◦ C for 30 s. The fold changes
were calculated based on 18S in the threshold cycle (Cq). Pertinent primer sequences are indicated in
Table 1.
Table 1. Primers for real time PCR.
Gene

Forward Sequence

Reserve Sequence

GRP78 (HSPA5)
Noxa (PMAIP1)
XBP1
CHOP (DDIT3)
CEBPB
ATF3
ATF4

CTGTCCAGGCTGGTGTGCTCT
CTGGAAGTCGAGTGTGCTACTC
CTGCCAGAGATCGAAAGAAGGC
GGTATGAGGACCTGCAAGAGGT
AGAAGACCGTGGACAAGCACAG
CGCTGGAATCAGTCACTGTCAG
TTCTCCAGCGACAAGGCTAAGG

CTTGGTAGGCACCACTGTGTTC
TGAAGGAGTCCCCTCATGCAAG
CTCCTGGTTCTCAACTACAAGGC
CTTGTGACCTCTGCTGGTTCTG
CTCCAGGACCTTGTGCTGCGT
CTTGTTTCGGCACTTTGCAGCTG
CTCCAACATCCAATCTGTCCCG

2.9. Chromatin Immunoprecipitation (CHIP) Sequencing
Chromatin immunoprecipitation (CHIP) sequencing was performed following the company’s
instructions (SimpleChIP® Enzymatic Chromatin IP Ki, CST 9003). Chromatin was immune-precipitated
with the following antibodies—H3K27ac (CST 4535, 10 µL/sample), H3K27Me3 (CST 9733, 10 µL/
sample), Rpb1 (CST 14958, 10 µL/sample) or Rabbit IgG (CST 2729, 2 µL/sample). Following purification,
the ChIP DNA was assessed for quality by real time PCR analysis. Libraries were prepared and
were subjected to next generation sequencing (Illumina HiSeQ instrument; HiSeq 4000; single read
50 bp (SR50)). Mapping to the human genome (hg38) was performed by bowtie2. Peaks were called
and obtained with MACS2 software. The BEDgraph files were converted to the bigwig format and
visualized with the Integrated Genome Browser (IGB). The experiment is deposited (GSE124877
and GSE150395).
2.10. Subcutaneous Xenograft Model
GBM12 and GBM43 glioblastoma patient-derived xenograft (PDX) tumors were injected into the
flanks of 6–8 weeks old Nu/Nu mice. Several subcutaneous tumors on each mouse were implanted.
Tumor and weight measurements were performed three times a week followed by intraperitoneal
administration of the compounds. The following dosages were administered—Panobinostat: 5 mg/kg;
Gamitrinib: 3 mg/kg. Drugs were dissolved in a mixture of drug (dissolved in DMSO), Kolliphor EL
(Sigma, 61791-12-6), Ethyl Alcohol 200 Proof (Pharmco-Aaper, 64-17-5) and PBS at the ratio: 10:32:8:50
(v/v/v/v). The length and width were obtained with a caliper and subsequent calculation based on the
formula—(length x width2 )/2. Weight measurements were only performed on three mice per group.
2.11. TUNEL and Ki67 Staining
The specimens were fixed in formalin and embedded in paraffin. Following dewaxing and
rehydration, the tumors were exposed to proteinase K (Agilent Dako, S3020). The processed slides
were exposed to TUNEL reaction mixture and the reaction was terminated in the converter peroxidase
(POD) solution. The chromogen, diaminobenzidine, was employed for visualization of the TUNEL
reaction. Background nuclear staining was established with hematoxylin. For Ki67 staining, samples
were incubated with Ki67 antibody (Agilent Dako, GA626).
2.12. Statistical Analysis
Statistical significance was assessed by Student’s t-test or ANOVA (for multiple comparison)
using Prism 8 (GraphPad, La Jolla, CA, USA). A p ≤ 0.05 was set as the level of statistical significance.
* p < 0.05, ** p < 0.01, ***/**** p < 0.001 while n. s. means not significant.
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2.13. Study Approval
All procedures were in accordance with Animal Welfare Regulations and approved by
the Institutional Animal Care and Use Committee at the Columbia University Medical Center
(AC-AABC6505).
3. Results
3.1. FDA Approved HDAC Inhibitors and the Mitochondrial Chaperone Inhibitor, Gamitrinib, Lead to a
Synergistic Reduction of Cellular Viability in Glioblastoma Models
Informed by a drug screen approach to define synthetic lethal interaction for the novel TRAP1
inhibitor, gamitrinib, we validated whether or not global or selective HDAC inhibitors induce synergistic
reduction of cellular viability in relevant model systems of human glioblastoma (Figure 1A–D).
To this purpose, we assessed cellular viability following treatment with the global HDAC inhibitor
panobinostat, gamitrinib (GTPP) and the combination of both reagents. While single treatment impacted
the survival, the combination treatment led to a synergistic reduction of cellular viability in established
glioblastoma cells, U87 and LN229 (Figure 1A,C). This occurred in a similar fashion, suggesting that
the genetic make-up of these tumor cells likely does not contribute to the efficacy of the combination
treatment in light of the fact that U87 are wild type TP53, whereas in contrast LN229 are mutated.
The TP53 status is relevant in that GBMs are commonly mutated in TP53, which may impact response
and resistance to therapy [1–3]. Similar observations were made in T98G that harbors TP53 mutations
(Figure S1A,B). We extended our experiments to a more clinically relevant scenario [15] by employing
short term patient-derived xenograft cell cultures, GBM12 and GBM43 (Figure 1A,C). Compared to
the established cell cultures, the GBM12 cells revealed a relatively pronounced susceptibility to both
gamitrinib and panobinostat. Nevertheless, the combination treatment still resulted in a synergistic
growth reduction. Following treatment with gamitrinib and panobinostat, the GBM43 cell cultures
revealed a synergistic loss of cellular viability as well. These results suggest that the combination
treatment of global HDAC inhibitors in combination with TRAP1 inhibitors are effective in reducing
the viability of a variety of GBM cells, likely to be irrespective of TP53 status.
A certain concern in drug combination therapies relates to off target effects, which in part is
implied by the term “global” HDAC inhibitors. Over the recent years, strategies have unfolded to block
targets in a more precise manner. Within the group of HDAC inhibitors, the FDA approved compound,
romidepsin, comes closer to this paradigm given that it inhibits both HDAC1 and HDAC2 in the low
nanomolar range. Consistently, we applied these low nanomolar concentrations of romidepsin for
our drug combination studies with gamitrinib. In the context of established GBM culture systems,
romidespin displayed a remarkable efficacy to reduce the cellular viability, which occurred in the very
low nano molar range. Remarkably, when romidepsin was combined with gamitrinib the reduction
was further enhanced in a synergistic manner in both TP53 wild type U87 as well as mutated LN229
and U251 GBM cells, respectively (Figure 1B,D and Figure S1C,D). Akin to panobinostat, we evaluated
the efficacy of single and combination treatments, involving romidepsin and gamtrinib, in short term
patient-derived xenograft cultures (Figure 1B,D and Figure S1C,D). In alignment with the results
obtained in established GBM cells romidepsin exerted a remarkable reduction of cellular viability
(again in the low nano molar range), which was synergistically enhanced by gamitrinib in both GBM12,
GBM43 and GBM14 cells.
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Finally, we asked whether the combination treatment would display enhanced cleavage/activation
of caspases and caspase substrate cleavage, respectively. While panobinostat revealed some cleavage
of initiator caspase-9, effector caspase 3 and PARP (substrate of activated caspase 3), the combination
treatment enhanced this further in U87, T98G and U251 GBM cells, in keeping with the results of
the flow cytometry based cell death assays (Figure 2D and Figure S4C,D). One of the issues in cell
death related research is to determine the requirements of the observed form of cell death, for example,
whether for instance the activation of caspases is indeed involved in the process or merely a bystander
effect. To address this question, we utilized the pan-caspase inhibitor, zVAD-fmk. We found that DNA
fragmentation induced by the combination treatment of gamitrinib and panobinostat was rescued by
concomitant treatment with zVAD-fmk, suggesting that caspases are indeed involved and necessary in
the process (Figure 2E and Figure S4E).
Although gamitrinib has been coined as a TRAP1 inhibitor we sought to confirm whether selective
genetic inhibition is sufficient to enhance HDAC inhibitor mediated induction of cell death. To this
purpose, we transfected U87 GBM cells with non-targeting or TRAP1 specific siRNA. Following
transfection, the cells were subjected to panobinostat treatment and following the incubation period
analyzed for cell death induction by annexin V/PI based flow cytometry (Figure 2F–H). In keeping
with earlier experiences, knockdown of TRAP1 on its own had very little effects on cell death induction
in the U87 GBM cells. In contrast, TRAP1 silencing significantly enhanced panobinostat mediated cell
death as compared to cells transfected with the non-targeting siRNA pool. In a parallel approach, we
analyzed the same experimental setup for loss of mitochondrial membrane potential (TMRE staining
with flow cytometric analysis) (Figure S4F,G). In keeping with the cell death findings, TRAP1 silencing
in the presence of panobinostat led to enhanced dissipation of the mitochondrial membrane potential.
Overall, these observations suggest that TRAP1 inhibition is sufficient to sensitize GBM cells for cell
death induction by HDAC inhibitors.
3.3. The Combination Treatment Modulates the Expression of the Bcl-2 Protein Family Members and
Pro-Apopotic Members of the Bcl-2 Family Members are Required for Cell Death Execution
Intrinsic apoptosis is modulated in part by Bcl-2 family members since they determine the
permeability of the outer mitochondrial membrane. Given that we noted a cell death with features of
apoptosis induced by the combination treatment, we evaluated the expression of the anti-apoptotic
Bcl-2 family members, Bcl-2, Bcl-xL and Mcl-1 in established and PDX GBM cells by utilizing protein
capillary electrophoresis and standard western blotting. In most instances, we noted a suppression of
the three anti-apoptotic Bcl-2 family members in established GBM cells (U87, T98G and U251) following
treatment with the combination treatment of gamitrinib and panobinostat as compared to vehicle
treatment (Figure 3A and Figure S5A–D). In contrast, pro-apoptotic Bcl-2 family members remained
either unchanged or increased. Next, we assessed how the combination treatment of gamitrinib
and the selective HDAC inhibitor, romidepsin, affects the expression of the Bcl-2-family members of
proteins. To this end, we treated the established and PDX GBM cells with the gamitrinib, romidepsin
or the combination of both (Figure 3B and Figure S5E,F). Akin to panobinostat, we found that the
combination treatment led to a decline in most anti-apoptotic proteins. We noted an exception to this
general pattern in GBM14 cells, in which there was an increase in Bcl-2 following the combination
treatment (Figure 3B and Figure S5E,F). With regards to the pro-apoptotic Bcl-2 family members, we
noted an up-regulation of BIM. Concerning Noxa, the expression pattern was more complicated with
some showing increased or constant expression or decreased levels (Figure 3B and Figure S5E,F). When
considering the ratio between pro-apoptotic Noxa and anti-apoptotic Mcl-1, the combination treatment
resulted in an increased ratio between the proteins in most instances when compared to the vehicle
treatments but for the most part no differential engagement between combination treatments and
single treatments (Figure S5A,C,F).
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3.4. The Combination Treatment of Gamitrinib and HDAC Inhibitor Mediates an Integrated Stress Response
The induction of cell death and the modulation of Bcl-2 family members is often preceded and
regulated by the so called integrated stress response, which may be induced by a number of factors,
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3.5. Combined Inhibition of HDAC and TRAP1 Modulates Tumor Cell Metabolism
Based on the literature and our own work, the integrated stress response is known to be related to
metabolism and our earlier work demonstrated a role for gamitrinib as well as panobinostat in GBM
metabolism [13,18]. Given that these effects are contrary to tumor cell respiration (i.e., panobinostat
increases, whereas gamitrinib suppresses the oxygen consumption rate (OCR)) through disruption
of the complex II of the respiratory chain (SDH), we hypothesized that gamitrinib might suppress
panobinostat mediated increase in oxygen consumption rate. To address this question, we utilized
the mitochondrial stress assay on the seahorse analyzer in U87 GBM cells. In this assay, basal OCR
measurements are taken, followed by injection of oligomycin (ATP-production), FCCP (maximal
respiration) and rotenone/antimycin (inhibition of mitochondrial respiration). After each injection of
these compounds the OCR values are recorded. U87 GBM cells were treated with vehicle, gamitrinib,
panobinostat or the combination of both (Figure 5A–C). Following treatment, the cells were subjected to
extracellular flux analysis. Basal measurements, maximal respiration and the OCR/ECAR (extracellular
acidification rate) ratio revealed an increase following treatment with panobinostat and a decrease
with gamitrinib (Figure 5B,C). The increase of the OCR/ECAR ratio by panobinostat is in keeping
with the reversal of the Warburg-effect, leading to suppression of ECAR and an increase of OCR.
Importantly, gamitrinib reversed panobinostat mediated increase of basal OCR, maximal respiration
and the OCR/ECAR ratio (Figure 5B,C). These data suggest that the combination treatment reduced
energy metabolism in GBM cells. Next, we asked about the mechanism by which panobinostat
facilitates an increase in OCR. While there are several possibilities, the first and foremost to consider
are the expression levels of respiratory complexes. To this end, U87 and LN229 GBM cells were treated
with vehicle, gamitrinib or the combination of both and following protein isolation analyzed for the
expression levels of the five respiratory complexes (Figure 5D and Figure S6A–C). While we detected
an increase of respiratory complexes following panobinostat treatment, gamitrinib counteracted this
up-regulation, which is in agreement with our findings obtained on the seahorse analyzer (Figure 5D
and Figure S6A–C). To validate that TRAP1 is directly involved in this phenomenon mediated by
gamitrinib, we silenced TRAP1 in U87 cells by two specific siRNAs (Figure 5E). Following transfection,
protein expression of both SDHA and SDHB was assessed by protein capillary electrophoresis,
demonstrating that TRAP1 silencing sufficed to suppress these two proteins that are associated with
complex two of the respiratory chain (Figure 5E). Previous findings from our group demonstrated that
panobinostat up-regulated SDHA and SDHB following acute and chronic treatment with panobinostat
and that the up-regulation is mediated on a transcriptional level [13]. Given that HDAC inhibitors
affect the post-translational status of histones and histones regulate the accessibility of the chromatin
we assessed the status of H3K27ac, H3K27me3 and RNA polymerase II (Rpb1) binding to the SDHA
and SDHB locus by chromatin immunoprecipitation coupled with next generation sequencing of
vehicle or panobinostat treated cells (Figure 5F). Regarding the SDHB locus, we noticed a modulation of
H3K27ac and a striking reduction of the repressive histone mark, H3K27me3 in panobinostat exposed
U87 cells (PbR). Consistently, this phenomenon was coupled with enhanced presence of Rbp1 at the
transcriptional start site of SDHB, facilitating mRNA production of SDHB (Figure 5F). Similar findings
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the
SDHA
locus.
2020, 9, xat
FOR
PEER
REVIEW
12 of 19

Figure 5. Cont.

Cells 2020, 9, 1661

12 of 18

FigureFigure
5. The
combination
treatment
HDACinhibitors
inhibitors
interferes
GBM
5. The
combination
treatmentofofgamitrinib
gamitrinib and
and HDAC
interferes
withwith
GBM
cell cell
energy
metabolism.
Mitochondrial stress
stress test
treated
withwith
gamitrinib,
panobinostat
or
energy
metabolism.
(A)(A)
Mitochondrial
testofofU87
U87cells
cells
treated
gamitrinib,
panobinostat
combinationofofboth
bothfor
for2424h.
OM: oligomycin,
oligomycin, FCCP:
(trifluoromethoxy)
or thethe
combination
h. OM:
FCCP:Carbonyl
Carbonylcyanide-4
cyanide-4
(trifluoromethoxy)
phenylhydrazone,
R/A:
rotenoneand
andantimycin
antimycin A
A (n
(n =
= 4);
andand
maximal
phenylhydrazone,
R/A:
rotenone
4); (B)
(B)The
Thebasal
basalrespiration
respiration
maximal
respiration
experimentinin(A)
(A) were
were calculated
(n (n
= 3,=4);3,(C)
is the OCR/ECAR
ratio fromratio
respiration
fromfrom
experiment
calculated
4);Shown
(C) Shown
is the OCR/ECAR
mitochondrial stress test of U87 cells treated with the indicated concentrations of gamitrinib,
from mitochondrial stress test of U87 cells treated with the indicated concentrations of gamitrinib,
panobinostat or the combination of both for 24h (n = 4). OCR: oxygen consumption rate, ECAR:
panobinostat or the combination of both for 24 h (n = 4). OCR: oxygen consumption rate, ECAR:
extracellular acidification rate (a surrogate for glycolytic activity); (D) U87 and LN229 cells were treated
extracellular acidification rate (a surrogate for glycolytic activity); (D) U87 and LN229 cells were treated
with gamitrinib, panobinostat or the combination of both for 24h and the whole cell lysates were
with gamitrinib,
panobinostat
the combination
bothasterisk
for 24 hindicates
and thea whole
lysatesofwere
subjected to protein
capillaryorelectrophoresis.
The of
double
strongercell
exposure
subjected
to
protein
capillary
electrophoresis.
The
double
asterisk
indicates
a
stronger
exposure
SDHB. Vinculin is the loading control for U87 and actin is the loading control for LN229.
The of
SDHB.expression
Vinculin islevels
the loading
control for
U87 and actin
is the loading
for LN229.
TheImageJ
expression
of V-ATP5A,
I-NDUFB8
and II-SDHB
werecontrol
quantified
by using
levels(shown
of V-ATP5A,
I-NDUFB8
and
II-SDHB
were
quantified
using ImageJ
(shown
in cursive
in cursive
font); (E)
U87
cells were
transfected
withby
non-targeting
(siNT)
or TRAP1
specificfont);
(E) U87
cells(siTRAP1)(single
were transfected
non-targeting
(siNT)
TRAP1
siRNA
(siTRAP1)(single
siRNA
or with
pool (p))
and the whole
cell or
lysates
werespecific
subjected
to protein
capillary
electrophoresis;
Shown
the respective
tracks ofto
ChIP
sequencing
around
SDHA and SDHB
of
or pool
(p)) and the (F)
whole
cellare
lysates
were subjected
protein
capillary
electrophoresis;
(F) Shown
parental
and panobinostat
treated
U87 GBM cells.
Highlighted
is theSDHB
transcriptional
startand
site (TSS)
by a
are the
respective
tracks of ChIP
sequencing
around
SDHA and
of parental
panobinostat
red
rectangle.
ShownHighlighted
are means and
was used
for the
***/**** p <Shown
0.001. are
treated
U87
GBM cells.
is SD.
the ANOVA
transcriptional
start
sitestatistical
(TSS) byanalysis.
a red rectangle.
means and SD. ANOVA was used for the statistical analysis. ***/**** p < 0.001.
3.6. The Combination Treatment of Gamitrinib and Panobinostat Reduces Tumor Growth More Potently than
Single
Treatments Treatment
in Glioblastoma
PDX Models
in Mice
3.6. The
Combination
of Gamitrinib
and
Panobinostat Reduces Tumor Growth More Potently than

Single Treatments
Glioblastoma
Modelswhether
in Mice the combination treatment of gamitrinib and
Finally, inwe
sought to PDX
determine
panobinostat
couldto
lead
to the reduction
tumor
growth intreatment
two patient-derived
xenograft
models
Finally,
we sought
determine
whetherofthe
combination
of gamitrinib
and panobinostat
of
human
GBM
in
mice.
To
this
end,
we
implanted
the
GBM12
PDX
line
in
the
flank
of
nude
mice.GBM
could lead to the reduction of tumor growth in two patient-derived xenograft models of human
Following establishment of the tumors, four groups were formed, consisting of vehicle, gamitrinib
in mice. To this end, we implanted the GBM12 PDX line in the flank of nude mice. Following
establishment of the tumors, four groups were formed, consisting of vehicle, gamitrinib (GTPP),
panobinostat (Pb) or the combination of both. We noted that single treatment caused a reduction
of tumor growth already (Figure 6A–C and Figure S7A). However, the combination treatment was
even more effective in limiting tumor growth compared to single treatments with either gamitrinib
or panobinostat (Figure 6A–C and Figure S7A). In a second GBM PDX model (GBM43), we made
slightly different findings. In the GBM43 model, we found a reduction of tumor growth only mediated
by panobinostat but not gamitrinib (Figure 6D–F and Figure S7B). Nevertheless, the combination
treatment led to a potent further reduction of tumor growth as compared to panobinostat. These results
demonstrate that the effect of the combination treatment on tumor growth is not limited to just one
model, consistent with our in vitro observations. Notably, we found no significant reduction in animal
weight and consistently, there was no damage imposed by the combination treatment on major organ
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These results demonstrate that the effect of the combination treatment on tumor growth is not limited
to just one model, consistent with our in vitro observations. Notably, we found no significant reduction
systems,
such as
heart,and
lung,
liver, kidney
asimposed
assessedbybythestandard
histological
in animal
weight
consistently,
thereand
was pancreas
no damage
combination
treatmentanalysis
on
(Figure
S7C).
We
examined
the
tumors
as
well
and
found
that
there
was
significant
distortion
of the
major organ systems, such as heart, lung, liver, kidney and pancreas as assessed by standard
tumorhistological
architecture
with(Figure
reduced
mitosis
and emergence
ofasnecrosis
the specimens
treated
with the
analysis
S7C).
We examined
the tumors
well andin
found
that there was
significant
distortion
of the tumor
architecture
with reduced
mitosis
and emergence
necrosis
in the (Figure
specimens
combination
treatment
(Figure
6G). Moreover,
a lower
amount
of mitosisofwas
identified
6G,H).
with the
combination
treatment by
(Figure
a lower(Figure
amount6I–L).
of mitosis
Thesetreated
observations
were
further confirmed
Ki67 6G).
and Moreover,
TUNEL staining
Whilewas
vehicle
identified
(Figure showed
6G,H). These
observations
were of
further
by Ki67
and
TUNEL staining
and single
treatments
many
large fractions
Ki67 confirmed
positive nuclei,
the
combination
revealed
(Figure
6I–L).
While
vehicle
and
single
treatments
showed
many
large
fractions
of
Ki67
nuclei,
far less (Figure 6I,J). In contrast, TUNEL staining demonstrated a higher number ofpositive
positive
nuclei in
the combination revealed far less (Figure 6I,J). In contrast, TUNEL staining demonstrated a higher
the combination treatment as compared to vehicle and single treatments (Figure 6K,L). These results
number of positive nuclei in the combination treatment as compared to vehicle and single treatments
implicate
that the combination treatment elicited its effects by reducing proliferation and induction of
(Figure 6K,L). These results implicate that the combination treatment elicited its effects by reducing
cell death
in a largely
tumor selective
manner
given tumor
that major
organ
systems
demonstrate
proliferation
and induction
of cell death
in a largely
selective
manner
givendid
thatnot
major
organ
signs systems
of toxicity
the treatment.
did following
not demonstrate
signs of toxicity following the treatment.

6. Combined
treatment
withgamitrinib
gamitrinib (GTPP)
(GTPP) and
panobinostat,
elicits
FigureFigure
6. Combined
treatment
with
and HDAC
HDACinhibitor,
inhibitor,
panobinostat,
elicits
enhanced
tumor
growth
inhibition in
in vivo.
vivo. (A)
Patient-derived
xenograft
tumors,tumors,
GBM12 cells
werecells
enhanced
tumor
growth
inhibition
(A)
Patient-derived
xenograft
GBM12
were implanted into the subcutis of immunocompromised Nu/Nu mice. After the tumors were
established, randomization was performed to define four treatment groups: vehicle, gamitrinib
(3 mg/kg), panobinostat (5 mg/kg) and the combination treatment. Shown are the tumor volumes over
time; (B,C) The graphs show tumor volume (n = 6–8) on the last day and the body weight (n = 3) of
the experiment in (A); (D) Patient-derived xenograft tumors, GBM43 cells were implanted into the
subcutis of immunocompromised Nu/Nu mice. After the tumors were established, randomization was
performed to obtain four treatment groups: vehicle, gamitrinib (3 mg/kg), panobinostat (5 mg/kg) and
the combination treatment. Shown are the tumor volumes over time; (E,F) The graphs show tumor
volume (n = 7–9) on the last day and the body weight (n = 3) of the experiment in (D); (G–L) Tumors
from the experiment in (D) were stained with H&E, TUNEL or Ki67. Quantifications are provided from
several high-power fields in H, J and L. Shown are means and SD. ANOVA was used for the statistical
analysis. * p < 0.05, ** p < 0.01, ***/**** p < 0.001.
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4. Discussion
The elucidation of more durable treatment modalities, including novel drug combination
therapies, for the treatment of GBM remains one of the highest priorities [2,3,19–26]. The present drug
combination, involving gamitrinib and HDAC inhibitors, appears to be effective against a broad range
of different GBM model systems, suggesting potentially broad applicability, particularly with regards
to heterogeneity. With the development of next generation sequencing, single cell sequencing and the
huge variety of small molecule compounds an array of opportunities has emerged [1]. Notwithstanding
these techniques, tumor cell metabolism has received significant attention in the field as well in light of
the notion that tumor cells develop distinct features that will allow them to grow relentlessly. One of
these metabolic effects is the Warburg effect [27] and our recent work demonstrated that global and
selective HDAC inhibitor disrupt this phenomenon by targeting super-enhancers in genes, such as
HK2, GAPDH and ENO1 [13]. Following treatment with HDAC inhibitors we noted incomplete cell
killing and the surviving GBM cells displayed a reduced glycolytic activity and in order to maintain
survival they facilitated tumor respiration, which in the present and earlier work we were able to link
to up-regulation of respiratory complexes [13]. In the present work, we expanded this concept further
by showing that apparently HDAC inhibitor treatment results in a loss of the repressive histone mark,
H3K27me, around the loci of SDH. The methyltransferase EZH2 is mostly known to modulate histone
methylation and is part of the PRC2 complex [28,29]. How the PRC2 complex is related to HDACs
has been recently demonstrated by others, revealing an interaction between HDAC2 and the PRC2
complex [30]. Once HDAC2 is inhibited the PRC2 complex becomes hyper-acetylated and dissociates
along with its ability to methylate histones [30], which in concert may result in less methylation of
H3K27 and thereby facilitate the up-regulation of genes. The current concept is also in line with the
recent observations that the expression of PPARGC1A, the master regulator of oxidative metabolism,
is controlled by the H3K27me3 mark [31,32].
The present work originated from the observation that based on a drug screen we made the
intriguing finding that HDAC inhibitors may enhance the killing efficacy of gamitrinib in tumor
cells [4]. Here, we established this concept by demonstrating that global (panobinostat) and selective
(romidepsin) HDAC inhibitors combined with gamitrinib synergistically reduced the viability of a
broad variety of GBM model systems. Given that gamitrinib is prominently known to interfere with
the electron transport chain, we hypothesized that gamitrinib and its target TRAP1 [18] could thwart
HDAC inhibitor induced activation of tumor respiration. In keeping with this notion, our findings here
demonstrated that gamitrinib attenuated increased GBM cell respiration facilitated by panobinostat.
What follows is the activation of an integrated stress response with characteristic activation of eif2α
signaling, culminating in an increase of the stress response transcription factor, ATF4 [33–35]. Although
our experiments did not directly connect these two phenomena, previous work by us and others has
demonstrated a tight linkage between energy deprivation (here mediated by dual loss of the major
energetic pathways) and the activation of the integrated stress response [36]. In part, loss of ATP is
linked due to accumulation of unfolded proteins given that proper maturation and protein synthesis
depend on an appropriate state of energy within cells and altering this rheostat will affect the integrity
of tumor cells [37].
The integrated stress response mediators ATF4 and ATF3 have been known to impact tumor cell
survival in part through regulation of the Bcl-2 family members of proteins [16,17]. Our silencing
experiments demonstrated the involvement of Noxa in cell death elicited by the combination treatment,
which is in keeping with certain other drug combination treatments [38–41]. In addition, we validated
the involvement of pro-apoptotic BAX and BAK in the drug combination through siRNA experiments
and it seems that BAK is particularly important for the combination treatment to exert its effects. These
results are in keeping with other studies that have demonstrated involvement of the Bcl-2 family of
proteins in cell killing since usually BAX and BAK are necessary for cell death induction under such
circumstances [38–41]. Although we have not pursued the approach of simultaneous inhibition of
both BAX/BAK, this strategy oftentimes results in an even stronger suppression of cell death induction
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by certain stimuli [42]. Classically, BH3-mimetics would be expected to be particularly prone to this
strategy since their mechanism of action depends on the release of BAX and BAK from either Bcl-2
and/or Bcl-xL [43,44]. Our finding that in GBM14 the drug combination of gamitrinib and romidespin
elicited an increase of Bcl-2 is intriguing when this observation is put into the context of BH3-mimetics,
especially the FDA-approved drug, venetoclax (ABT-199). It would be tempting to speculate that
presumably ABT-199 might further enhance the efficacy of the drug combination of gamitrinib and
romidepsin. Future studies may address such an approach further.
We also confirmed that the combination treatment acted in PDX models of human GBM [3] to
reduce tumor growth without any major toxicity event. These results are reassuring in that other
drug combinations, involving gamitrinib, have performed reasonably well in terms of efficacy, while
at the same time displaying minimal toxicity. For instance, we have recently demonstrated that the
combination treatment of gamitrinib and the BH3-mimetic, ABT263, has extended overall survival in
an orthotopic PDX model of GBM in mice [45]. Similarly, we found that activation of LXR receptors
along with interference of TRAP1 led to enhanced growth reduction of heterotopic xenograft of GBM in
mice [46]. Other groups have demonstrated that gamitrinib enhanced the efficacy of BRAF-inhibitors in
model systems of melanoma in part by the ability of gamitrinib to dampen tumor cell respiration [47].
How efficient gamitrinib and/or panobinostat penetrate the blood brain barrier (BBB) has not formally
been documented. However, given that brain tumors disrupt the BBB, it is likely that at the very least
a significant fraction of glial tumor cells may be exposed to the drugs. However, additional more
detailed liquid chromatography/mass spectrometry (LC/MS) studies would be necessary to determine
the degree of penetration.
5. Conclusions
Combined inhibition of TRAP1 and HDACs is a potential novel strategy to combat recalcitrant
malignancies, such as GBM. We have unraveled a mechanism that relates to tumor cell metabolism,
the integrated stress response and modulation of Bcl-2 family members, which all in all resulted in the
induction of a caspase dependent cell death with apoptotic features.
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